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cell–cell interactions in an in vitro condi-
tion is cocultures.[4,7] However, different 
cell types inevitably mix in cocultures, and 
this contamination often complicates anal-
yses and obscures results.[8,9] In addition, 
because of the complex and uncontrol-
lable nature of the method, it is difficult to 
precisely manipulate the degree of hetero-
typic interactions.
ESCs are often regulated by stimuli 
from feeder cultures. For example, stimuli 
from mouse embryonic fibroblasts (mEFs) 
contribute to the self-renewal of ESCs, and 
stimuli from OP9 and PA6 cells contribute 
to hematopoietic and neuronal lineage-
specific differentiation of ESCs, respec-
tively.[10–12] Although soluble factors, such 
as cytokines, and small chemicals, such 
as retinoic acids, have been purified and 
used for feeder-free cultures of ESCs, no other methods cur-
rently exist that provide cells with contact-dependent stimuli, 
except the coculture method.[13–15] Therefore, a continuing need 
exists for a new method to overcome the problems of the cocul-
ture method in ESC research.
A number of methods have been developed to meet this need 
in ESC research. Some studies showed that a part of contact-
dependent stimuli can be replaced by different combinations 
of extracellular matrices (ECMs).[16–18] However, ECMs cannot 
provide cell-specific stimuli which are mediated by membrane-
associated proteins, and these approaches have been utilized 
only in limited numbers of applications.[19] Some recent studies 
have also utilized chemically fixed feeder layers, but they still 
did not successfully recreate cell-specific contact-dependent 
stimuli and may cause undesired effects by fixatives.[20,21]
As a viable alternative, we developed a method that uses 
cell-engineered nanovesicles (CNVs), which possess similar 
lipid and protein compositions to their originating cells. To 
produce such vesicles, we applied the serial extrusion method 
to cells and separated vesicle fractions by density-gradient 
ultracentrifugation, which has been previously used to pro-
duce liposomes.[22,23] Produced CNVs are freely diffusible in 
culture media, and can be precisely quantified in terms of par-
ticle counts or protein amounts. By treating ESCs with CNVs 
made from mEF, OP9 and PA6 stromal cells, we can induce 
feeder-related ESC regulations in the absence of living cells. 
In addition, from the result that CNVmEF was fully functional 
only in the presence of leukemia inhibitory factor (LIF), we con-
firmed that the effects of CNV treatment are mainly induced 
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Stem Cell Regulation
1. Introduction
Heterotypic interactions between cells play crucial roles in 
the developmental and immunological processes of multicel-
lular organisms.[1–3] For example, stimuli for lineage-specific 
differentiation of embryonic stem cells (ESCs) are often pro-
vided by heterotypic interactions.[3,4] Cells in a shared space 
continuously exchange stimuli through direct cell–cell contacts 
(juxtacrine stimuli) and/or secreting soluble factors (paracrine 
stimuli).[5,6] Therefore, recreating these interactions in a labo-
ratory setting is essential in many research fields, as well as 
cell cultures. The most commonly used method to reconstitute 
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by the physical contacts, and that soluble factors are of lesser 
importance.
2. Results
2.1. Characterization of CNVs
Three different stromal cells (mEF, OP9, and PA6) were seri-
ally extruded through track-etched polycarbonate filters having 
10 and 5 µm pores. The extruded solutions containing vesicles 
were then subjected to Opti-prep density-gradient ultracen-
trifugation. CNV fractions were separated from the interface 
between 10% and 30% density solutions (Figure 1a). Purified 
CNVs were then quantified using Bradford protein assay, and 
aliquots of CNVs were stored at −80 °C for up to three months 
for further use. The stability of stored CNVs was confirmed 
by comparing the size and protein profiles of fresh and stored 
CNVs (Figure S1, Supporting Information). Each batch of CNVs 
was confirmed not to have any viable cells prior to storage to 
prevent unwanted effects caused by cell-mixings (Figure S2, 
Supporting Information).
The morphologies of CNVs made from mEF (CNVmEF), OP9 
(CNVOP9), and PA6 (CNVPA6) were confirmed using transmis-
sion electron microscopy (TEM) with uranyl acetate negative 
staining. All three types had similar diameters of 100–200 nm, 
and were generally spherical structures enclosed by lipid 
membranes (Figure 1b). Nanoparticle tracking analysis (NTA) 
results of the three CNVs were consistent with TEM results; 
their sizes ranged from ≈50 nm to a few hundred nanometers, 
with a peak at ≈150 nm (Figure 1c). Coomassie blue staining of 
sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) results 
of cell and CNV lysates showed almost no differences; this 
similarity means that the protein compositions of CNVs were 
the same as those of their originating cells (Figure 1f). How-
ever, it also revealed that the protein composition of extracel-
lular vesicles (EVs) was different from those of both the cells 
and CNVs (Figure 1f). When CNVs were produced from a cell-
line that stably expresses palmitoylated-mCherry (localized at 
the plasma membrane) and GFP (localized in the cytoplasm), 
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Figure 1. Production and characterization of CNVs. a) Schematic of CNV production. Cells were collected from cultures and serially extruded through 
track-etched microporous filters. CNVs were isolated from the extrudate by using density gradient ultracentrifugation. b) Transmission electron micro-
scopic visualization of CNVmEF, CNVOP9, and CNVPA6. Scale bars: 200 nm. c) Nanoparticle tracking analysis. The sizes of produced CNVs (CNVmEF, 
CNVOP9, and CNVPA6) were measured using NTA. Black solid lines: mean values; gray areas: ± S.D. d) Membrane-to-cytoplasm ratio of CNVs. HEK293 
cells that stably expressed cytoplasmic GFP and palmitoylated mCherry, and CNVs made from this HEK293 cells were imaged under epifluorescence 
microscope (images). Scale bars: 50 µm; Error bars: +S.D. e) The membrane-to-cytoplasm (mCherry-to-GFP) ratio was quantified using a multi-plate 
reader (graph). f) Coomassie blue analysis of EVs, CNVs, and cell. The SDS-PAGE patterns of CNVs and cells were very similar, but the SDS-PAGE 
pattern of EVs was completely different from them.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1700381 (3 of 10)
www.advancedsciencenews.com www.advhealthmat.de
CNVs exhibited an ≈10 times higher membrane-to-cyto-
plasm (mCherry-to-GFP) ratio than did their originating cells 
(Figure 1d,e).
2.2. Characterization of Cell–CNV Interaction
Produced CNVs were mixed with cell-culture media and applied 
to in vitro cultured cells. CNVs located near cells can come into 
physical contact with them. If the surface proteins of CNVs and 
the cells interact, the CNVs and cells will bind and exchange 
stimuli (Figure 2a). To identify the presence of such interac-
tion between cells and CNVs, we treated cells with DiI-labeled 
CNVs. First, we used confocal microscopy to visually confirm 
the physical contacts between the cells and CNVs. 10 min after 
CNV treatment, red fluorescent signals of DiI-stained CNVs 
emerged, and 30 min after CNV treatment, most of the cells 
made physical contacts with CNV with red fluorescence signals 
(Figure 2b). To quantify the degree of cell–CNV interaction, we 
utilized flow cytometry to analyze the DiI-CNV-treated cells. 
The DiI signal accumulated until 12 h after treatment, and then 
plateaued and decreased slightly (Figure 2c).
To determine whether the cell–CNV interactions can induce 
downstream signal transduction pathways, we performed 
western phosphorylation activity in short-term culture with a 
CNV treatment, and for AKT phosphorylation activity in long-
term culture with repeated CNV treatments. In western blots 
after a CNV treatment, the amount of p-MAPK noticeably was 
increased in the treated cells, and in western blots after mul-
tiple CNV treatments, the amount of p-AKT was increased 
slightly in the treated cells (Figure 2d). In cells treated with 
CNVs made from cells that had been treated with trypsin 
for 1 h, the phosphorylation of both the MAPK and AKT was 
significantly reduced; this result implies that phosphorylation 
of MAPK and AKT was induced by proteins on the CNV sur-
faces (Figure 2d).
2.3. CNVmEF Treatment for ESC Self-Renewal
CNVs were produced from in vitro cultured mEFs. To test the 
ability of CNVmEF to maintain pluripotency, we examined the 
morphology and OCT3/4 expressions of ESCs treated with 
CNVmEF. First, we performed the experiment in the absence of 
LIF, which is a crucial soluble factor that helps ESC to maintain 
their pluripotency.[14] On the 3rd day, the CNV-treated groups 
showed no increase in OCT3/4 expression, which was signifi-
cantly lower than that of the ESCs cultured with mEF feeder 
layers (Figure 3a). In both the CNVmEF-treated groups and non-
treated groups, the cell morphologies dramatically changed, 
and their doubling times increased noticeably; these results 
imply that the ESCs had lost their self-renewing abilities and 
had begun to differentiate (data not shown).
We performed a similar experiment in the presence of LIF. 
In this condition, CNVmEF successfully maintained the pluripo-
tency of ESCs. Under a phase-contrast microscope, the groups 
treated with ≥50 µg mL−1 CNVmEF exhibited well-maintained 
dome-like ESC morphologies until the 12th day of culture 
(Figure S4a, Supporting Information). Flow cytometric analyses 
of OCT3/4 protein expression of the same cells showed sim-
ilar results; groups treated with 50 and 100 µg mL−1 CNVmEF 
showed similar or even higher OCT3/4 protein expressions 
than did feeder-culture groups (Figure 3b). Treatment of CNV 
also reduced the doubling time of ESC to a level similar to that 
of ESCs cultured on a mEF feeder layer (Figure S5, Supporting 
Information). The number of cells in the nontreated groups 
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Figure 2. Characterization of CNVs and of cell–CNV interaction. a) Schematic of CNV–cell interaction. When cells and CNVs are closely located, they 
physically interact. b) Confocal microscopic analysis of CNV-cell interaction. CFSE (green) labeled ESCs were treated with DiI (red) labeled CNVmEF. 
DiI-labeled CNVs almost completely surrounded the cells 30 min after treatment. Scale bars: 50 µm. c) Flow cytometric analysis of CNV–cell interaction. 
More than half of the cells were positive for DiI-labeled CNV signals at 1 h after the treatment, and most cells were positive for the signal at 12 h after 
treatment. d) Phosphorylation of Mitogen- Activated Protein Kinase (MAPK) by short-term CNV treatment (left). mEFs were treated with ES CNVs for 
30 min. The phosphorylation of MAPK increased in a dose-dependent manner. Treatment with trypsinized CNVs did not induce phosphorylation of 
MAPK. Phosphorylation of Protein Kinase B (AKT) by long-term CNV treatment (right). ESCs were treated with CNVmEF five times for 10 d. The phos-
phorylation of AKT was increased by these treatments. Treatment using trypsinized CNVs did not induce phosphorylation of AKT.
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decreased substantially because they had differentiated and lost 
their self-renewing ability.
To further confirm the efficiency of CNVmEF during a pro-
longed culture, we performed alkaline phosphatase (ALP) 
staining and immunofluorescence labeling of OCT3/4 and 
SOX2 after 24 d of culture. In the mEF feeder culture groups 
and CNVmEF-treated groups, the expressions of ALP, OCT3/4, 
and SOX2 were well maintained even after 24 d of culture. In 
the nontreated groups, however, ALP expression decreased, and 
OCT3/4 and SOX2 expressions almost disappeared (Figure 3c). 
To evaluate the pluripotency of the cells, ESCs maintained 
using CNVs for >21 d were exposed to a differentiation con-
dition. The differentiation ability of CNV-treated ESCs was the 
same as that of properly-maintained ESCs. They successfully 
differentiated into all three germ layers, and the mRNA expres-
sion levels of early germ-layer markers were almost identical 
to those of properly maintained ESCs (Figure 3d; Figure S6, 
Supporting Information). ESCs maintained without mEF 
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Figure 3. Pluripotency maintenance of ESCs after treatment with CNVmEF. a) Flow cytometric analysis of OCT3/4 transcription factors after CNVmEF 
treatment in the absence of LIF. After two CNVmEF treatments over 3 d, the percentage of ESCs that expressed pluripotency-related protein OCT3/4 was 
quantified by flow cytometry. Treatment using 100 µg mL−1 CNVmEF did not maintain pluripotency. n = 3, bars = + S.D. b) Flow cytometric analysis of 
OCT3/4 transcription factors after CNVmEF treatment in the presence of LIF. After six CNV treatments for 12 d, the percentage of ESCs that expressed 
OCT3/4 was measured using flow cytometry. Treatment using 100 µg mL−1 CNVmEF was found to be optimal for maintenance of ESC pluripotency. n = 3, 
bars = + S.D. c) Microscopic analysis of pluripotency markers. ALP staining and immunofluorescent labeling of OCT3/4 and SOX2 were performed 
using ESCs cultured for 24 d in different conditions. The expressions of ALP, OCT3/4, and SOX2 in ESCs treated with 100 µg mL−1 CNVmEF were 
similar to those of appropriately maintained ESCs. The nontreated group showed decreased ALP expression, and OCT3/4 and SOX2 expressions were 
absent. Scale bars: 200 µm. d) Relative mRNA expression level of Oct3/4, Hand1, Sox1, and Gata4 in differentiated ESCs that had been maintained 
with CNVmEF and mEF feeders. ESCs maintained with CNVmEF showed almost an identical degree of three germ layer differentiation abilities as those 
of appropriately maintained ESCs. n = 3, error bars: +S.D.
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feeder layers or CNVmEF did not survive for 21 d; they spontane-
ously differentiated during the culture period and failed to form 
embryoid bodies (data not shown).
2.4. CNVOP9 Treatment for the Hematopoietic Differentiation 
of ESC
CNVs were produced from in vitro cultured OP9 cells, which 
are known to induce ESCs to differentiate into hematopoi-
etic lineages.[11] On the 1st day of CNV treatment, culture 
media were changed to hematopoietic differentiation media. 
To optimize the CNV treatment condition, ESCs were treated 
with different amounts of CNVOP9 for 6 d of culture. On the 
6th day, the groups that had been treated with ≥50 µg mL−1 
CNVOP9 exhibited distinct colonies of spherical and protruding 
cells, which also appeared in the OP9 feeder culture group 
(Figure S4b, Supporting Information). However, the highest 
dose (200 µg mL−1) seemed to be toxic to the ESCs (Figure S4b, 
Supporting Information). The cells were collected from the cul-
ture, and early mesodermal gene expressions of the cells were 
confirmed by Quantitative reverse transcription-Polymerase 
Chain Reaction (RT-qPCR). The expressions of Flk1 and Scl 
genes were increased in a dose-dependent manner by CNVOP9, 
but decreased at the dose of 200 µg mL−1. Therefore, the 
100 µg mL−1 CNVOP9 dose was found to be optimal for meso-
dermal lineage differentiation (Figure 4a).
On the 17th day of culture with 100 µg mL−1 CNVOP9, 
the number of spherical and protruding hematopoietic lin-
eage cells in the CNV-treated groups seemed to exceed the 
number of such cells in OP9 feeder cultures, but nontreated 
groups showed irregular morphologies and mixed types of cells 
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Figure 4. Hematopoietic differentiation of ESCs by treatment with CNVOP9. a) RT-qPCR analysis of mesodermal genes after CNVOP9 treatment. 
After two CNVOP9 treatments, relative gene expressions of two mesodermal genes Flk1 and Scl were measured using RT-qPCR. Treatment using 
100 µg mL−1 CNVOP9 was optimal for mesodermal differentiation. n = 3, bars: +S.D. b) Morphologies of ESCs cultured for 17 d with/without CNVOP9. 
ESCs cultured without CNVOP9 showed heterogeneous morphologies of three germ layer cells on the 17th day of culture. ESCs cultured with CNVOP9 or 
OP9 feeder layers showed homogeneous blood cell-like morphologies on the 17th day of the culture. Scale bars: 200 µm. c) Flow-cytometry analyses of 
hematopoietic progenitor cell markers on the 17th day of the culture. Cells from the 17th day of the culture were stained with c-KIT, SCA1, and CD45 
hematopoietic progenitor markers, and analyzed by flow cytometry. d) Flow cytometry analyses of mature blood cell markers on the 17th day of the 
culture. The same cells were also stained with MAC1 macrophage marker, GR1 granulocyte marker, TER119 erythrocyte marker, B220 B lymphocyte 
marker, and CD3 T lymphocyte marker, and then analyzed using a flow cytometer.
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(Figure 4b). Among the cells collected on the same day, hemat-
opoietic progenitor cells that expressed c-KIT, SCA-1, and CD45 
were detected by flow cytometric analyses. Among all of the 
groups, the CNV-treated groups exhibited the largest number 
of such cells (Figure 4c). On the 17th day, myeloid lineage 
cell (positive for Mac-1 macrophage marker, GR-1 granulocyte 
marker, and Ter119 erythrocyte marker) and lymphoid lineage 
cell (positive for B220 B lymphocyte marker and CD3 T lym-
phocyte marker) were also detected. The portions of these cells 
from the CNVOP9-treated groups were generally similar to the 
portion of the cells from feeder layer groups, but the nontreated 
cultures showed almost no (<2%) mature hematopoietic lineage 
cells (Figure 4d). The existence of various hematopoietic lineage 
cells in the CNVOP9-treated and feeder layer groups was recon-
firmed by DIFF-QUIK stained microscopic images (Figure S7, 
Supporting Information). Unlike the previous CNVmEF case, 
groups treated with CNVOP9 without the addition of additives, 
such as cytokines, exhibited similar or superior hematopoietic 
differentiation induction ability to that of the feeder groups.
2.5. CNVOP9 Treatment for the Neuronal Differentiation of ESC
When PA6 cells are used as feeder layers, they induce ESCs 
to differentiate into neuronal cells.[12] To test the ability of 
CNVPA6 to induce neuronal differentiation, we produced 
CNVs from in vitro cultured PA6 cells and applied them to 
ESCs with a neural differentiation medium. To determine the 
optimal condition for CNVPA6 treatment, ESCs were treated 
with different doses of CNVPA6 for 4 d. Groups treated with 
CNVPA6 showed comparatively mild phenotypic changes; as 
the dose of CNVs increased, the number of aggregated bodies 
increased, but cells treated with 200 µg mL−1 CNVs seemed 
to be dying (Figure S4c, Supporting Information). The expres-
sion of ectodermal genes Nestin, Pax6, and Sox1 were ana-
lyzed in cells treated with CNVPA6. The expressions of all 
three genes increased in a manner dependent on CNV dose, 
except at 200 µg mL−1 CNVPA6, in which case they decreased 
(Figure 5a). Because 100 µg mL−1 CNV-treated groups exhib-
ited similar or higher ectodermal gene expressions to that of 
the feeder layer groups, the 100 µg mL−1 dose was optimal 
(Figure 5a).
On the 8th day of culture with the 100 µg mL−1 CNVPA6 dose, 
ESCs showed comparatively homogenous spindle-like mor-
phology; whereas, nontreated groups showed hetero geneous 
morphologies composed of all three germ-layer-like cells 
(Figure 5b). When these cells were labeled with neuron-specific 
TUJ1 antibodies, groups treated with CNVPA6 showed almost 
the same numbers and morphologies of neurons as groups 
treated with PA6 feeder layers, but nontreated groups showed 
far fewer TUJ1-positive cells than did the other two groups 
(Figure 5b). To quantitatively assess the efficacy of treatment 
with CNVPA6, we calculated the percentage of TUJ1-positive 
colonies in low-magnification fluorescent microscopic images. 
The percentage of TUJ1-positive colonies was almost the same 
in CNV-treated groups and feeder-culture groups, and both 
were significantly (one-way ANOVA; F(2,6) = 31.86, p < 0.001) 
(≈5 times) higher than in nontreated groups (Figure 5c). 
Groups treated with CNVPA6 without any additional substances 
exhibited almost identical neural differentiation induction 
ability to that of the feeder cultures.
3. Discussion
CNVs were developed and used as a delivery vehicle in pre-
vious studies because of its small size and vesicle-like struc-
ture.[23–26] In this study, apart from the delivery-related aspect, 
we rather focused on the natural characteristics of CNVs that 
support carrying active cell-specific proteins for inducing cell-
specific effects. The presence and relative abundance of plasma 
membrane in CNVs were confirmed using cells expressing 
fluorescent proteins in their plasma membrane and cytoplasm 
(Figure 1d,e). In addition, the treatment of CNVs made from 
trypsin-digested cells clearly showed that the effect of CNVs 
was mainly induced by the proteins on the plasma membrane 
(Figure 2d). Taking these two results together, we can reason-
ably speculate that the effector proteins of CNVs might be car-
ried on their membrane rather than lumen.
On contact with living cells, these active proteins on the 
CNV surface give the same contact-dependent stimuli that 
would be given by their originating cell (Figure 2a). Studies of 
EVs or exosomes have reported similar concepts.[27] Some of 
the previous CNV studies highlighted that CNVs and EVs share 
many characteristics.[23,25] However, according to our analyses, 
CNVs and EVs share only a few physical characteristics, such as 
size and structure, but their protein compositions are different: 
CNVs are more similar to cells than are EVs (Figure 1f). Con-
sidering that the CNVs were produced by randomly breaking 
cells, but the EVs were produced by a complicated biological 
process, this difference in characteristics is to be expected. 
Moreover, treatment using EVs isolated from mEF did not 
induce the same effects as treatment with CNVs and living 
feeder cells (Figure S3, Supporting Information). Therefore, we 
conclude that CNVs are more likely to be cell-like nanovesicles 
that carry active signaling proteins than are exosomes and EV-
like natural messengers. To understand further difference and 
similarity between CNVs and EVs, more studies are necessary 
in future.
In typical cell–cell interactions, cells exchange various stimuli 
through physical contacts, by secreted soluble factors, or both. 
If a stimulus from a cell–cell interaction is entirely mediated 
by physical contact between cells, the use of CNVs may replace 
the function of one cell, and may improve the efficiency of the 
interaction (Figures 4a and 5a), possibly because cell–CNV 
interactions have larger interaction surfaces and higher possi-
bilities of interaction than do cell–cell interactions (Figure 2a). 
When secreted soluble factors are crucial for cell–cell interac-
tions, the use of CNVs, instead of cells, will compromise the 
efficiency of interactions, or will not induce any interactions 
at all because CNVs cannot produce or secrete soluble factors. 
According to our results, CNVOP9 and CNVPA6 treatments suc-
cessfully induced ESCs to differentiate into hematopoietic and 
neuronal cells without any additives; thus, in these cells, the 
effects of physical contact are dominant. In contrast, CNVmEF 
treatment only reproduced the effect of mEF feeder layers in 
the presence of LIF. This result suggests that some of the het-
erotypic cell–cell interaction between mEF and ESC is mediated 
Adv. Healthcare Mater. 2017, 6, 1700381
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by soluble factors, which might not be successfully induced by 
the CNVs. These explanations actually correspond well with 
previous reports that demonstrated that mEF affects ESCs both 
by physical contact and by soluble factors, while PA6 mainly 
affects ESCs by physical contact and matrix deposition.[10,12]
Numerous soluble factors in cell–cell interactions have 
been discovered and produced as recombinant proteins. For 
example, recombinant LIF and basic fibroblast growth factor 
have been utilized to maintain ESC self-renewal, and various 
interleukins and colony-stimulating factors have been used to 
induce hematopoietic differentiation of ESCs.[13,14,28] In con-
trast, as of yet, no other methods have been identified that can 
induce cell-specific contact-dependent stimuli, except coculture 
methods. Some studies have attempted to solve this problem 
by using different combinations of ECMs because some part of 
contact-dependent stimuli are actually induced by ECMs.[16–18] 
However, these methods did not provide cell-specific contact-
dependent stimuli mediated by membrane-associated proteins 
of cells, and therefore they have succeeded only in limited 
applications.[19] Furthermore, since the membrane-associated 
molecules of feeder cells that might induce ESC-regulating 
stimuli have not yet been clearly identified, approaches using 
defined or purified proteins would not be suitable for providing 
such cell-specific contact-dependent stimuli.[19]
The CNV method that we demonstrated in this study consti-
tutes an effective and novel approach. CNVs can be produced 
from all types of cells. Therefore, if hard to culture cells such 
as primary cells were used to produce CNVs, we could effec-
tively transmit their stimulus without culturing them. Pro-
duced CNVs can be also stored at −80 °C for at least three 
months without noticeable loss of their biological activity. In 
addition, CNVs can freely diffuse like soluble factors or EVs, 
and the amount of CNVs can be precisely quantified in terms 
of particle counts or protein amounts. For these reasons, CNVs 
can be used simply by mixing them in culture media, which 
is the same manner in which other soluble factors are used. 
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Figure 5. Neuronal differentiation of ESCs after treatment using CNVPA6. a) RT-qPCR analysis of ectodermal genes after PA6 CNV treatment. After 
two CNVPA6 treatments, relative gene expressions of three ectodermal genes Nestin, Pax6, and Sox1 were measured using RT-qPCR. Treatment using 
100 µg mL−1 CNVPA6 was optimal for ectodermal differentiation. n = 3, bars: +S.D. b) Morphologies of ESCs cultured for 8 d with/without CNVPA6. On 
the 8th day of culture, ESCs cultured without CNVPA6 showed heterogeneous morphologies of mixed three germ layer cells, whereas ESCs cultured 
with CNVPA6 or PA6 feeder layers showed homogeneous spindle-like morphologies. Scale bars: 200 µm. Labelling these cells with neuron-specific TUJ1 
antibodies emphasized their morphological differences: ESCs cultured without CNVPA6 showed very few TUJ1-positive cells, but ESCs cultured with 
CNVPA6 and PA6 feeder layers showed increased numbers of TUJ1-positive cells. Scale bars: 200 µm. c) The percentage of TUJ1-positive colonies on 
the 8th day of the cultures, as counted in low-magnification images. Bars labeled with the same letter are not significantly different (p < 0.01); n = 3, 
error bars: +S.D.
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Because, unlike feeder layers, CNVs are freely diffusible, they 
might be also mixed in suspension cultures such as blood cell 
cultures and bioreactors to provide contact dependent stimulus. 
By adjusting the concentration of CNVs in culture media, the 
amount of stimuli given to treated cells can also be manipu-
lated, which is almost impossible in the case of conventional 
coculture method. Due to this scalability, we were able to opti-
mize CNV concentrations in terms of protein amounts in all 
cases. Although we tested the ability of CNV methods only with 
mouse ESCs, it can be expected to be used in various other 
applications. In this study, we successfully reproduced three 
different cocultures consist of different sets of cells and having 
different mechanism of actions. Based on the results, we can 
assume that the CNV method has potential to reproduce other 
pre-established cocultures including human ESCs.[29–31]
4. Conclusion
The optimized CNV treatments successfully induced contact-
dependent stimuli in the absence of living cells, and they led 
to changes in ESCs to the directions that we anticipated. In 
addition, CNVs can be utilized in combination with other cul-
ture additives, such as cytokines and ECMs. In such combina-
tion, they can compensate for the weaknesses of each other’s 
methods and produce substantially better results.
5. Experimental Section
Cell Culture: C57BL/6 mouse ESC, ES-D3 mouse ESC, and OP9 cell 
lines were purchased from ATCC. MC3T3-PA6 (PA6) cells were purchased 
from RIKEN Bioresource Center. mEFs were isolated from 13.5 d old 
C57BL/6 mouse embryos.[32] The procedures using mice were approved by 
the Institutional Animal Care and Use Committee at POSTECH, Pohang, 
Republic of Korea (approval number: 2013-01-0016). C57BL/6 and ES-D3 
mouse ESCs were maintained on mEF feeder cells in ES media: knock-out 
Dulbecco Modified Eagle Medium (KO DMEM, Gibco) supplemented 
with 15% knock-out serum replacement (KOSR, Gibco), 1% penicillin–
streptomycin (PS, Gibco), 4 × 10−3 m l-glutamine (Sigma-Aldrich), 
0.1 × 10−3 m 2-mercaptoethanol (2-ME, Sigma-Aldrich), and 1000 U mL−1 
LIF (ORF Genetics). mEF cells were maintained in DMEM (Gibco) 
supplemented with 10% Fetal Bovine Serum (FBS, Hyclone) and 1% PS. 
OP9 cells were maintained in Minimum Essential Media (MEM-α, Gibco) 
supplemented with 20% FBS and 1% PS. PA6 cells were maintained in 
MEM-α supplemented with 10% FBS and 1% Penicillin-Streptomycin. 
All cells were cultured on a tissue culture dish coated with 0.2% gelatin. 
The mEF and OP9 feeder layers were prepared by treating confluent 
monolayers of cells with 10 µg mL−1 mitomycin C for 2 h at 37 °C. PA6 
feeder layers were used without additional growth-arrest procedure.
CNV Production: To preserve membrane proteins, mEF, OP9, 
and PA6 cells were harvested using nonenzymatic 2 × 10−3 m 
Ethylenediaminetetraacetic acid (EDTA)/phosphate buffered saline 
(PBS). The cells were centrifuged at 500 ×g for 10 min at RT, and 
suspended (2 × 107 cells mL−1) in PBS. To produce DiI-labeled CNVs, 
cells were stained at this step with vibrant DiI dye according to the 
manufacturer’s instructions. To produce trypsinized CNVs, cells were 
tripsinized for 30 min at 37 °C, and then extruded five times each through 
10 and 5 µm pore polycarbonate track-etched membrane (Whatman) 
that were installed in a mini-extruder (Avanti). The extruded cells were 
precleaned by centrifugation at 500 × g for 10 min to remove unbroken 
cells. The supernatants were then applied to iodixanol (Opti-perp, 
AXIS-SHIELD) density-gradient ultracentrifuge. Briefly, 1 mL of 10% 
iodixanol solution was layered on top of 1 mL 30% iodixanol solution 
in a 5 mL ultracentrifuge tube for SW55Ti rotor (Beckman Coulter). The 
precleaned supernatants were then layered on top of the preformed 
density gradient and ultracentrifuge with SW55Ti rotor at 100 000 × g 
for 2 h at 4 °C. The CNVs were obtained from the layer between the 10% 
and 30% iodixanol. The amount of CNVs was quantified using Bradford 
protein assay (Sigma-Aldrich). Produced CNVs were mixed with full-
growth media and cultured for 3 d in an empty 6 well plate at a 5% CO2 
incubator. After 3 d of culture, the plate was visually inspected under 
phase contrast microscope and double checked with CCK-8 cell viability 
test kit. Aliquots of CNVs could be stored for at least three months at 
−80 °C for further use.
TEM: TEM (JEOL) was used to visualize the morphologies of 
CNVs. CNVs were dried on a formvar carbon film (FCF300-cu, Electron 
Microscopy Science), and then negatively stained using 7 µL of 2% 
uranyl acetate for 10 s. Samples were dried for at least 30 min, and then 
imaged at 60 kV acceleration voltage.
NTA: The numbers and sizes of CNVs were measured using NTA 
(Nanosight LM10, Malvern Instruments). The CNVs were diluted in PBS 
until appropriate numbers of CNVs were detected, and then recorded 
five times.
Fluorescence Intensity Measurement: Fluorescence intensity of HEK293 
cells that expressed palmitoylated mCherry and cytoplasmic GFP, and 
CNVs made from this cell line were measured using a multiplate reader 
(DTX880, Beckman). Filter sets for GFP and mCherry measurement 
were 488/535 and 535/595 (ex/em), respectively.
Confocal Microscopy: For confocal microscopy of cells treated with 
CNVs, cells were labeled with a CFSE cell tracer (Molecular Probes), and 
CNVs were labeled with DiI lipophilic dye (Thermo Fisher Scientific). 
After treatment, cells were fixed with 4% paraformaldehyde and counter 
stained with Hoechst (Sigma-Aldrich). Cross-section images were 
obtained using a confocal microscope (Olympus).
Coomassie Blue Staining: EV, CNV, cell were lysed using 
1×Radioimmunoprecipitation assay (RIPA) buffer, and then quantified 
using a bicinchoninic acid assay kit (BCA, Thermo Fisher Scientific). 
The isolated proteins were then denatured by boiling at 100 °C for 
10 min, then separated on SDS-PAGE using electrophoresis at 100 V for 
2 h. The gel was then transferred in fixing solution (50% methanol and 
10% glacial acetic acid) for 10 min. After washed in water 3 times with 
distilled water, the gel was soaked in staining solution (0.1% coomassie 
brilliant blue, 50% methanol, and 10% glacial acetic acid) for 30 min 
with gentle agitation. Finally, the gel was soaked in destaining solution 
(40% methanol and 10% glacial acetic acid) with gentle agitation and 
then transferred to fresh destaining solution. The destaining process 
was repeated until background of the gel was destained.
Western Blot: For western blot to detect phosphorylation of MAPK by 
short-term CNV treatment, mEFs were serum-starved for 12 h, and then 
treated with CNVESC for 30 min. For western blot to detect phosphorylation 
of AKT by long-term CNV treatment, ESCs were treated with CNVmEF five 
times for 10 d. The cells were then lysed using 1× RIPA buffer. Proteins 
were quantified using a BCA. The isolated proteins were denatured by 
boiling at 100 °C for 10 min, and then separated on SDS-PAGE using 
electrophoresis at 100 V for 2 h. Separated protein was then transferred 
to a polyvinylidene fluoride membrane at 390 mA for 2 h. The proteins 
were incubated with 5% nonfat milk in 0.05% tween-20 tris-buffered saline 
(TBST) for 1 h at RT. AKT and MAPK antibodies were diluted 1:1000 
in 5% nonfat milk in 0.05% TBST; p-AKT and p-MAPK antibodies were 
diluted 1:500 in 1% nonfat milk in 0.05% TBST. Diluted antibodies were 
incubated overnight at 4 °C, and then washed three times with 0.05% 
TBST. HRP conjugated secondary antibodies (Santa Cruz) were diluted 
1:5000 in 5% nonfat milk in 0.05% TBST, and then incubated for 1 h at RT. 
The immune-reactive bands were detected by applying chemiluminescent 
substrate (Amersham Pharmacia Biotech) to the membrane. Antibodies 
used in this research are listed in Table S1 (Supporting Information).
CNVmEF Treatment Conditions: First, ESCs were treated with CNVmEF 
in the absence of LIF. ESCs were treated with CNVmEF every 2 d with 
medium change for 3 d. On the 3rd day, cells were observed under 
phase-contrast microscope IX71 (Olympus) and applied to OCT3/4 
flow cytometric analysis. Second, ESCs were treated with CNVmEF 
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in the presence of LIF every 2 d for 24 d. On the 12th day, cells were 
observed under phase contrast microscope and applied to OCT3/4 
flow cytometric analysis. On the 24th day, cells were stained for ALP, 
OCT3/4, and SOX2, and observed under a fluorescence microscope 
IX71 (Olympus). The cells from the 24th day were also applied to EB 
formation and differentiation.
CNVOP9 Treatment Conditions: ESCs were treated with CNVOP9 in 
hematopoietic differentiation medium (MEM-α supplemented with 
20% FBS, 1% PS, 0.1 × 10−3 m 2-ME and 1% nonessential amino acids). 
Feeder control groups were cultured as previously described.[33] CNVOP9 
were applied every 3 d for 17 d. On the 6th day, cells were observed 
under phase-contrast microscope and applied to RT-qPCR for Flk1 
and Scl for dose optimization. On the 17th day, cells were observed 
under phase-contrast microscope, and harvested for flow cytometric 
analyses of c-KIT, SCA1, CD45, MAC1, GR1, TER119, B220, and CD3 
hematopoietic cell markers (PCR primers and antibodies are listed in 
Tables S1 and S2 in the Supporting Information).
CNVPA6 Treatment Conditions: ESCs were treated with CNVPA6 in neural 
differentiation medium (KO DMEM supplemented with 15% KOSR, 1% 
PS, 4 × 10−3 m l-glutamine, and 0.1 × 10−3 m 2-ME). Feeder control groups 
were cultured as previously described.[12] CNVPA6 were applied every 
2 d for 8 d. On the 4th day, cells were observed under phase-contrast 
microscope and applied to RT-qPCR for Nestin, Pax6, and Sox1 for dose 
optimization. On the 8th day, cells were observed under phase-contrast 
microscope, and stained for TUJ1 neuron marker for visualization 
(PCR primers and antibodies are listed in the Supplementary data). 
Fluorescence images were taken, and then ImageJ software (NIH) was 
used to calculate the percentage of TUJ1 positive colonies.
RT-qPCR: RNAs were isolated using Isol-RNA reagent (5 PRIME). The 
concentrations of isolated RNAs were quantified using a SimpliNano 
(GE). A reverse transcription kit (Promega) was used to generate 
cDNAs from the RNAs. Quantitative PCR was conducted using the 
MyiQ Real-time PCR Detection System (Bio-Rad) and iQ SYBR Green 
Supermix (Bio-Rad). Expression levels of all genes were normalized to 
the expression of β-actin. Primers used in RT-qPCR are listed in Table S2 
(Supporting Information).
Flow Cytometry: Immunostained samples were analyzed using an 
LSR Fortessa flow cytometer (BD Biosciences). All data were analyzed 
and plotted using Flowing software (http://www.uskonaskel.fi/
flowingsoftware/).
Immunostaining: The cell cultures were fixed with 4% 
paraformaldehyde (Sigma-Aldrich) for 10 min at RT, and then washed 
three times with 0.05% Tween 20 in PBS (0.05% PBST). Then, 0.2% 
Triton X-100 (Sigma-Aldrich) in PBS was added to each sample for 
10 min at RT to permeabilize the cells, which were then washed three 
times with PBST. Samples were incubated in blocking solution (5% 
FBS in PBS, 5% horse serum in PBS, or 3% BSA in PBS) at RT for 1 h. 
The samples were incubated with primary antibody solutions overnight 
at 4 °C, and then washed three times with PBST. Secondary antibodies 
were added to the samples and incubated at RT for 1 h, and then the 
samples were washed three times with PBST. The samples were counter-
stained with Hoechst (Sigma-Aldrich) at RT for 10 min, and then washed 
three times with PBST. Images were observed using a fluorescence 
microscope IX71 (Olympus). Antibodies used in this research are listed 
in Table S1 (Supporting Information).
Statistical Analysis: All statistical analyses were performed using 
R software (https://www.r-project.org/). The normality of the results 
was tested using the Shapiro–Wilk normality test. The homogeneity of 
variances of the results was tested using Levene’s test. The statistical 
significance of the results was analyzed using one-way between-groups 
analysis of variance, and significance between pairs was analyzed using 
Tukey’s HSD post hoc tests.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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